What makes a biotech domain valuable?
Durability across the pipeline. A therapeutics company usually starts in one modality and ends somewhere else, so a name welded to a single mechanism ages badly. Broad scientific roots — genome, therapeutics, precision, helix — keep working through a platform pivot in a way that a mechanism-specific coinage does not.
Institutional legibility matters more here than in most categories. The name appears in regulatory filings, hospital procurement documents and grant applications long before it appears in an advertisement, and each of those readers is checking for seriousness rather than personality.
JapanTherapeutics.com and SaudiTherapeutics.com attach the pharma category root to a jurisdiction, which is how national pharma and CDMO ventures are typically positioned.